TSXV:RTI.H - Post by User
Comment by
truthseeker0420on Nov 23, 2017 11:52am
64 Views
Post# 27019437
RE:RE:How can Radient compete with InMed Pharmaceutical?
RE:RE:How can Radient compete with InMed Pharmaceutical?The publication, titled, "Biotechs Develop Proprietary Systems to Drive CBD Research and Development," discusses biotech companies focused on the development of proprietary systems and procedures to drive research and production of cannabinoid pharmaceuticals. "One of the leading companies in this sector is InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) ( IMLFF Profile ), which has created proprietary systems for bioinformatics and biosynthesis manufacturing of pharmaceutical-grade cannabinoids. NEW YORK, NY--(Marketwired - Nov 9, 2017) - NetworkNewsWire("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in a proprietary in-house cannabinoid biosynthesis platform capable of producing any of the 90+ "downstream" cannabinoids that occur naturally in the cannabis plant.
The publication, titled, "Cannabis Biotechs Could be Big Pharma's Latest M&A Focus," discusses the operations of five cannabis biotech companies, several of which have been part of recent M&A activity.